Hide Board Information

Show Board Information

Immutep Limited IMMP

Board Mod: Add me as mod

Asst Mods:

Last Post: 05/24/2023 10:45:38 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 4

Immutep Limited (NASDAQ: IMMP) Stock Message Board

1. IMMP Company Profile

    

2. IMMP Time & Sales

    

3. IMMP Recent News

    

4. IMMP Filings

    

5. IMMP Financials

    

6. IMMP Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

6	$IMMP Hod2.73 nice	znewcar1	05/24/2023 10:45:38 AM
5	$IMMP 64% v77,8M c2.62 f87,929M H3.90 ML1.5	znewcar1	05/17/2023 4:24:27 PM
4	IMMP 39% v104M c3.68 f64,8M preMH4.2 morning dip	znewcar1	03/25/2021 5:09:36 PM
3	IMMP 163% v280M c5.69 f49,2M H7.95 S5.25 gap n go	znewcar1	12/10/2020 4:16:15 PM
2	IMMP 18% v5,5M c1.89 f48,7M preMH2.16 then dumped	znewcar1	09/18/2020 5:17:30 PM
1	IMMP 40% v4,3M c1.08 f38,8M H1.29 S@1 sideways	znewcar1	04/14/2020 4:37:44 PM

Recent Articles

• Significant Internet Disruptions Across Asia and Middle East
• Tether's CEO Denies Bitcoin Sales, Eyes Future Investments
• Exciting Updates from Faraday Future Ahead of 919 Futurist Day
• Fujitsu Launches Innovative AI Technology for Energy Efficiency
• Elon Musk's Vision: Tesla's Advanced AI Chips Transforming Tech
• Cryptocurrency Markets React To Key Economic Influences
• Epigenic Therapeutics Secures $60 Million to Enhance Therapies
• Danaher Corporation Faces Investigation for Fiduciary Duties
• WSPN's Strategic Acquisition of Aplauz NL B.V. Enhances Growth
• Shigeru Ishiba's Resignation: A New Era for Japan's Trade Policies
• Sunset World Group's Commitment to Sea Turtle Conservation Efforts
• InnoCare Pharma's Breakthrough Approval for HIBRUKA in Singapore
• Innovent Unveils Encouraging Phase 2 Study Results for Tigulixostat
• Hugel Expands Its Reach with Strategic Partnership in Brazil
• Exploring Recent Challenges for Telix Pharmaceuticals: What Investors Need to Know
• Lucid Gravity SUV Launch: A New Era for Electric Vehicles
• ACM Research Launches First High-Throughput Lithography System
• Abaxx Technologies and Qingdao International Energy Exchange Unite
• Baidu Plans New CNY-Denominated Notes Offering for Investors
• RxSight, Inc. Investors Alert: Secure Counsel Before Deadline
• Unlocking Compliance: The Future of Risk Management with AI
• DataGlobal Hub's Virtual Conference Presents AI Innovations
• Aiwyn Strengthens Its Influence with the QuickFee Acquisition
• Dianthus Therapeutics Set to Present Phase 2 MaGic Trial Insights
• Dianthus Therapeutics Boosts Hope for Myasthenia Gravis Patients
• Operation Warp Speed: A Game-Changer in Global Health
• An Inspiring Celebration Awaits: Explore LIGHT OF THE WORLD
• How Operation Warp Speed Paved the Path to Global Recovery
• Legal Insights: Dow Inc. Shareholders and Class Action Basics
• C3.ai Investors Invited to Join Class Action Against Company
• Cytovale's IntelliSep Accelerates Early Sepsis Detection Efforts
• Investors of CTO Realty Growth Should Act by Deadline
• Understanding Coffee's Value: More Than Just A Daily Habit
• Newsmax's Antitrust Complaint Against Fox News Dismissed
• Job Trends Shift: Staying Might Be the New Path to Pay Growth
• Investors of Lineage, Inc. Urged to Act Before Class Action Deadline
• European Fine on Google Sparks American Investment Debate
• ECOVACS Reveals Innovative DEEBOT X11 with PowerBoost Tech
• FDA Implements New Measures for GLP-1 Weight Loss Medications
• CATL Unveils Shenxing Pro: A Breakthrough for E-Mobility
• Stand Up Against Hate: A Movement for Religious Unity
• Paramount's Innovative Approach to Cable Networks in Streaming Era
• Join the Bumble Inc. Investigation and Protect Your Rights
• EHang Holdings Limited: Investors Investigated for Securities Violations
• Hypershell X Ultra: A Revolution in Outdoor Exoskeletons
• Exploring the Trend of Overemployment as Job Security
• Charter Communications Faces Legal Challenges: Class Action Alert
• Novo Nordisk Class Action Reminder: Investor Options Explained
• Market Signals: A Look into Silver and Economic Challenges
• Replimune Investors Alerted to Key Class Action Lawsuit Details